{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-004080","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.743602+00:00","generated_at":"2026-05-24T01:42:02.721826+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"confidence":"high","headline":"KALA BIO posts Q4 net loss of $8.2M; Phase 2b topline data delayed to 3Q25","bullets":["Randomized 87 patients in Phase 2b CHASE trial for KPI-012; extending enrollment due to 13 unverified patients; topline data now expected in 3Q25.","Raised $10.75M in December private placement with SR One, Cormorant, Woodline.","Cash and equivalents $51.2M at year-end; expected to fund operations into 1Q26.","Q4 operating loss $9.5M; net loss $8.2M ($1.74/share).","Full year 2024 net loss $38.5M ($10.15/share); no revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-004080","json":"https://secwatch.observer/filing/0001558370-25-004080.json","markdown":"https://secwatch.observer/filing/0001558370-25-004080.md","text":"https://secwatch.observer/filing/0001558370-25-004080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000155837025004080/0001558370-25-004080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000155837025004080/kala-20250331x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:42:02.721826+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}